A Phase 3 study evaluating sigvotatug vedotin for non-small cell lung cancer reached primary completion on 2026-05-18. This trial, which enrolled 762 participants, compared sigvotatug vedotin against docetaxel in previously treated patients.
Background
The study investigated sigvotatug vedotin, an experimental antibody drug, for participants with nonsquamous non-small cell lung cancer (NSCLC). Participants in this study had cancer that had spread or could not be surgically removed. They had previously been treated with no more than a platinum-based chemotherapy and an anti-PD-(L)1 drug. Patients with tumors having certain treatable genomic alterations also required at least one drug for that alteration, in addition to platinum-based chemotherapy.
Trial design
The Phase 3 study (NCT06012435) enrolled 762 participants with non-small cell lung cancer. The trial's primary objective was to compare the efficacy and safety of sigvotatug vedotin against docetaxel in patients who had received prior treatments for their advanced disease. The study is currently listed as ACTIVE_NOT_RECRUITING.
What this means
The primary completion of this Phase 3 study indicates that all planned data collection for the primary endpoint has concluded. While this marks a significant milestone in the development of sigvotatug vedotin for non-small cell lung cancer, no efficacy or safety results are available at this time. The next steps typically involve comprehensive data analysis, which will then inform future announcements regarding the trial's findings. Clinicians and researchers will need to await the release of these results to understand the potential role of sigvotatug vedotin in treating this patient population.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT06012435, titled "A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer", was posted on 2026-05-18 on clinicaltrials.gov.